secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001062993-26-001347
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed provides 2026 pipeline outlook; pre-IND meetings targeted for INM-901 and INM-089
--------------------------------------------------------------------------------

- Preclinical data for INM-901 shows reduced neuroinflammatory biomarkers, neuroprotection, and behavioral improvements in Alzheimer's models.
- Targeting pre-IND meeting with FDA for INM-901 in Q3 2026 and for INM-089 in Q4 2026.
- INM-901 aims for IND submission and Phase 1 clinical trial initiation in 2027.
- INM-089 (dry AMD) completed dose-ranging studies; drug substance process in place for IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/0001062993-26-001347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-001347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer